CSIMarket
 
Connect Biopharma Holdings Limited  (CNTB)
Other Ticker:  
 
 
Price: $1.3000 $0.18 16.071%
Day's High: $1.3 Week Perf: 12.07 %
Day's Low: $ 1.11 30 Day Perf: 8.33 %
Volume (M): 162 52 Wk High: $ 2.84
Volume (M$): $ 210 52 Wk Avg: $1.09
Open: $1.11 52 Wk Low: $0.53



 Market Capitalization (Millions $) 71
 Shares Outstanding (Millions) 55
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -114
 Cash Flow (TTM) (Millions $) 245
 Capital Exp. (TTM) (Millions $) 4

Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited is a biotechnology company based in China. The company specializes in the development of novel therapies for the treatment of autoimmune and inflammatory diseases. Their research focuses on understanding the underlying mechanisms of these diseases and developing targeted therapies to address them.

Connect Biopharma has a proprietary platform called Immune Modulation Technology (IMT) that enables the discovery and development of highly selective and potent antibody-based therapeutics. The IMT platform utilizes a combination of genomics, proteomics, and data analytics to identify disease-specific targets and develop antibodies that specifically modulate these targets.

The company has a pipeline of potential drug candidates targeting various autoimmune diseases, including inflammatory bowel disease, atopic dermatitis, and asthma. Some of their lead candidates are currently in clinical trials, with promising results reported so far.

Connect Biopharma has also entered into partnerships with other pharmaceutical companies to further develop and commercialize their drug candidates. They have collaborations with global biopharmaceutical companies, academic institutions, and contract research organizations to accelerate the development and commercialization of their therapies.

Overall, Connect Biopharma Holdings Limited is an innovative biotech company focused on developing novel therapies for autoimmune and inflammatory diseases. Their proprietary technology and strategic partnerships position them well in the competitive biopharmaceutical industry.


   Company Address: 12265 El Camino Real San Diego 92130 CA
   Company Phone Number: 727-1045   Stock Exchange / Ticker: NASDAQ CNTB
   CNTB is expected to report next financial results on April 10, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Connect Biopharma, a global clinical-stage biopharmaceutical company, has recently announced positive topline results from their Phase 2b trial evaluating the efficacy and safety of their drug, rademikibart, in adult patients with moderate-to-severe persistent asthma The company is dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research

Published Tue, Dec 12 2023 11:00 AM UTC

Connect Biopharma, a global clinical-stage biopharmaceutical company, has recently announced positive topline results from their Phase 2b trial evaluating the efficacy and safety of their drug, rademikibart, in adult patients with moderate-to-severe persistent asthma. The company is dedicated to improving the lives of patients with chronic inflammatory diseases through the d...

Clinical Study

Connect Biopharma's Rademikibart Shows Promise as a Breakthrough Treatment for Atopic Dermatitis in China Trial

Published Tue, Nov 21 2023 11:00 AM UTC

Connect Biopharma Announces Positive Long-Term Data from China Trial, Boosting Prospects for Rademikibart in Atopic Dermatitis Treatment
Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company, has released positive topline results from the Stage 2 of its China pivotal trial evaluating the efficacy and safety of rademikibarts (formerly know...

Clinical Study

Connect Biopharma's Radical Breakthrough: Unveiling Long-Term Data of Rademikibart's Efficacy in Treating Moderate-to-Severe Atopic Dermatitis

Published Mon, Nov 20 2023 9:41 PM UTC

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 - Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company focused on developing therapies derived from T cell-drive...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com